Global Myotonic Dystrophy Medication Market Research Report 2023

Myotonic Dystrophy Medication Market

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Myotonic Dystrophy Medication market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Myotonic Dystrophy Medication market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Myotonic Dystrophy Medication Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Myotonic Dystrophy Medication Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Sodium Channel Blocker

1.2.3 Tricyclic Antidepressant

1.2.4 Other

1.3 Market by Application

1.3.1 Global Myotonic Dystrophy Medication Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Myotonic Dystrophy Medication Market Perspective (2018-2029)

2.2 Myotonic Dystrophy Medication Growth Trends by Region

2.2.1 Global Myotonic Dystrophy Medication Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Myotonic Dystrophy Medication Historic Market Size by Region (2018-2023)

2.2.3 Myotonic Dystrophy Medication Forecasted Market Size by Region (2024-2029)

2.3 Myotonic Dystrophy Medication Market Dynamics

2.3.1 Myotonic Dystrophy Medication Industry Trends

2.3.2 Myotonic Dystrophy Medication Market Drivers

2.3.3 Myotonic Dystrophy Medication Market Challenges

2.3.4 Myotonic Dystrophy Medication Market Restraints

3.1 Global Top Myotonic Dystrophy Medication Players by Revenue

3.1.1 Global Top Myotonic Dystrophy Medication Players by Revenue (2018-2023)

3.1.2 Global Myotonic Dystrophy Medication Revenue Market Share by Players (2018-2023)

3.2 Global Myotonic Dystrophy Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Myotonic Dystrophy Medication Revenue

3.4 Global Myotonic Dystrophy Medication Market Concentration Ratio

3.4.1 Global Myotonic Dystrophy Medication Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Medication Revenue in 2022

3.5 Myotonic Dystrophy Medication Key Players Head office and Area Served

3.6 Key Players Myotonic Dystrophy Medication Product Solution and Service

3.7 Date of Enter into Myotonic Dystrophy Medication Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Myotonic Dystrophy Medication Historic Market Size by Type (2018-2023)

4.2 Global Myotonic Dystrophy Medication Forecasted Market Size by Type (2024-2029)

5.1 Global Myotonic Dystrophy Medication Historic Market Size by Application (2018-2023)

5.2 Global Myotonic Dystrophy Medication Forecasted Market Size by Application (2024-2029)

6.1 North America Myotonic Dystrophy Medication Market Size (2018-2029)

6.2 North America Myotonic Dystrophy Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Myotonic Dystrophy Medication Market Size by Country (2018-2023)

6.4 North America Myotonic Dystrophy Medication Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Myotonic Dystrophy Medication Market Size (2018-2029)

7.2 Europe Myotonic Dystrophy Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Myotonic Dystrophy Medication Market Size by Country (2018-2023)

7.4 Europe Myotonic Dystrophy Medication Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Myotonic Dystrophy Medication Market Size (2018-2029)

8.2 Asia-Pacific Myotonic Dystrophy Medication Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2018-2023)

8.4 Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Myotonic Dystrophy Medication Market Size (2018-2029)

9.2 Latin America Myotonic Dystrophy Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Myotonic Dystrophy Medication Market Size by Country (2018-2023)

9.4 Latin America Myotonic Dystrophy Medication Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Myotonic Dystrophy Medication Market Size (2018-2029)

10.2 Middle East & Africa Myotonic Dystrophy Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2018-2023)

10.4 Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Lupin

11.1.1 Lupin Company Detail

11.1.2 Lupin Business Overview

11.1.3 Lupin Myotonic Dystrophy Medication Introduction

11.1.4 Lupin Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.1.5 Lupin Recent Development

11.2 Teva

11.2.1 Teva Company Detail

11.2.2 Teva Business Overview

11.2.3 Teva Myotonic Dystrophy Medication Introduction

11.2.4 Teva Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.2.5 Teva Recent Development

11.3 ANI Pharmaceuticals

11.3.1 ANI Pharmaceuticals Company Detail

11.3.2 ANI Pharmaceuticals Business Overview

11.3.3 ANI Pharmaceuticals Myotonic Dystrophy Medication Introduction

11.3.4 ANI Pharmaceuticals Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.3.5 ANI Pharmaceuticals Recent Development

11.4 Viatris

11.4.1 Viatris Company Detail

11.4.2 Viatris Business Overview

11.4.3 Viatris Myotonic Dystrophy Medication Introduction

11.4.4 Viatris Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.4.5 Viatris Recent Development

11.5 Novartis

11.5.1 Novartis Company Detail

11.5.2 Novartis Business Overview

11.5.3 Novartis Myotonic Dystrophy Medication Introduction

11.5.4 Novartis Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.5.5 Novartis Recent Development

11.6 Sun Pharma

11.6.1 Sun Pharma Company Detail

11.6.2 Sun Pharma Business Overview

11.6.3 Sun Pharma Myotonic Dystrophy Medication Introduction

11.6.4 Sun Pharma Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.6.5 Sun Pharma Recent Development

11.7 Mallinckrodt

11.7.1 Mallinckrodt Company Detail

11.7.2 Mallinckrodt Business Overview

11.7.3 Mallinckrodt Myotonic Dystrophy Medication Introduction

11.7.4 Mallinckrodt Revenue in Myotonic Dystrophy Medication Business (2018-2023)

11.7.5 Mallinckrodt Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Myotonic Dystrophy Medication Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Sodium Channel Blocker

    Table 3. Key Players of Tricyclic Antidepressant

    Table 4. Key Players of Other

    Table 5. Global Myotonic Dystrophy Medication Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Myotonic Dystrophy Medication Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Myotonic Dystrophy Medication Market Size by Region (2018-2023) & (US$ Million)

    Table 8. Global Myotonic Dystrophy Medication Market Share by Region (2018-2023)

    Table 9. Global Myotonic Dystrophy Medication Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 10. Global Myotonic Dystrophy Medication Market Share by Region (2024-2029)

    Table 11. Myotonic Dystrophy Medication Market Trends

    Table 12. Myotonic Dystrophy Medication Market Drivers

    Table 13. Myotonic Dystrophy Medication Market Challenges

    Table 14. Myotonic Dystrophy Medication Market Restraints

    Table 15. Global Myotonic Dystrophy Medication Revenue by Players (2018-2023) & (US$ Million)

    Table 16. Global Myotonic Dystrophy Medication Market Share by Players (2018-2023)

    Table 17. Global Top Myotonic Dystrophy Medication Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Medication as of 2022)

    Table 18. Ranking of Global Top Myotonic Dystrophy Medication Companies by Revenue (US$ Million) in 2022

    Table 19. Global 5 Largest Players Market Share by Myotonic Dystrophy Medication Revenue (CR5 and HHI) & (2018-2023)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Myotonic Dystrophy Medication Product Solution and Service

    Table 22. Date of Enter into Myotonic Dystrophy Medication Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Myotonic Dystrophy Medication Market Size by Type (2018-2023) & (US$ Million)

    Table 25. Global Myotonic Dystrophy Medication Revenue Market Share by Type (2018-2023)

    Table 26. Global Myotonic Dystrophy Medication Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 27. Global Myotonic Dystrophy Medication Revenue Market Share by Type (2024-2029)

    Table 28. Global Myotonic Dystrophy Medication Market Size by Application (2018-2023) & (US$ Million)

    Table 29. Global Myotonic Dystrophy Medication Revenue Market Share by Application (2018-2023)

    Table 30. Global Myotonic Dystrophy Medication Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 31. Global Myotonic Dystrophy Medication Revenue Market Share by Application (2024-2029)

    Table 32. North America Myotonic Dystrophy Medication Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 33. North America Myotonic Dystrophy Medication Market Size by Country (2018-2023) & (US$ Million)

    Table 34. North America Myotonic Dystrophy Medication Market Size by Country (2024-2029) & (US$ Million)

    Table 35. Europe Myotonic Dystrophy Medication Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. Europe Myotonic Dystrophy Medication Market Size by Country (2018-2023) & (US$ Million)

    Table 37. Europe Myotonic Dystrophy Medication Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Asia-Pacific Myotonic Dystrophy Medication Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2018-2023) & (US$ Million)

    Table 40. Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2024-2029) & (US$ Million)

    Table 41. Latin America Myotonic Dystrophy Medication Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Latin America Myotonic Dystrophy Medication Market Size by Country (2018-2023) & (US$ Million)

    Table 43. Latin America Myotonic Dystrophy Medication Market Size by Country (2024-2029) & (US$ Million)

    Table 44. Middle East & Africa Myotonic Dystrophy Medication Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Lupin Company Detail

    Table 48. Lupin Business Overview

    Table 49. Lupin Myotonic Dystrophy Medication Product

    Table 50. Lupin Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 51. Lupin Recent Development

    Table 52. Teva Company Detail

    Table 53. Teva Business Overview

    Table 54. Teva Myotonic Dystrophy Medication Product

    Table 55. Teva Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 56. Teva Recent Development

    Table 57. ANI Pharmaceuticals Company Detail

    Table 58. ANI Pharmaceuticals Business Overview

    Table 59. ANI Pharmaceuticals Myotonic Dystrophy Medication Product

    Table 60. ANI Pharmaceuticals Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 61. ANI Pharmaceuticals Recent Development

    Table 62. Viatris Company Detail

    Table 63. Viatris Business Overview

    Table 64. Viatris Myotonic Dystrophy Medication Product

    Table 65. Viatris Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 66. Viatris Recent Development

    Table 67. Novartis Company Detail

    Table 68. Novartis Business Overview

    Table 69. Novartis Myotonic Dystrophy Medication Product

    Table 70. Novartis Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 71. Novartis Recent Development

    Table 72. Sun Pharma Company Detail

    Table 73. Sun Pharma Business Overview

    Table 74. Sun Pharma Myotonic Dystrophy Medication Product

    Table 75. Sun Pharma Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 76. Sun Pharma Recent Development

    Table 77. Mallinckrodt Company Detail

    Table 78. Mallinckrodt Business Overview

    Table 79. Mallinckrodt Myotonic Dystrophy Medication Product

    Table 80. Mallinckrodt Revenue in Myotonic Dystrophy Medication Business (2018-2023) & (US$ Million)

    Table 81. Mallinckrodt Recent Development

    Table 82. Research Programs/Design for This Report

    Table 83. Key Data Information from Secondary Sources

    Table 84. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Myotonic Dystrophy Medication Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Myotonic Dystrophy Medication Market Share by Type: 2022 VS 2029

    Figure 3. Sodium Channel Blocker Features

    Figure 4. Tricyclic Antidepressant Features

    Figure 5. Other Features

    Figure 6. Global Myotonic Dystrophy Medication Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Myotonic Dystrophy Medication Market Share by Application: 2022 VS 2029

    Figure 8. Hospital Pharmacy Case Studies

    Figure 9. Retail Pharmacy Case Studies

    Figure 10. Other Case Studies

    Figure 11. Myotonic Dystrophy Medication Report Years Considered

    Figure 12. Global Myotonic Dystrophy Medication Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 13. Global Myotonic Dystrophy Medication Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Myotonic Dystrophy Medication Market Share by Region: 2022 VS 2029

    Figure 15. Global Myotonic Dystrophy Medication Market Share by Players in 2022

    Figure 16. Global Top Myotonic Dystrophy Medication Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Medication as of 2022)

    Figure 17. The Top 10 and 5 Players Market Share by Myotonic Dystrophy Medication Revenue in 2022

    Figure 18. North America Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. North America Myotonic Dystrophy Medication Market Share by Country (2018-2029)

    Figure 20. United States Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Canada Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Myotonic Dystrophy Medication Market Share by Country (2018-2029)

    Figure 24. Germany Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. France Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. U.K. Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Italy Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Russia Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Nordic Countries Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Myotonic Dystrophy Medication Market Share by Region (2018-2029)

    Figure 32. China Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Japan Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. South Korea Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Southeast Asia Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. India Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Australia Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Myotonic Dystrophy Medication Market Share by Country (2018-2029)

    Figure 40. Mexico Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Brazil Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Myotonic Dystrophy Medication Market Share by Country (2018-2029)

    Figure 44. Turkey Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Saudi Arabia Myotonic Dystrophy Medication Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Lupin Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 47. Teva Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 48. ANI Pharmaceuticals Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 49. Viatris Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 50. Novartis Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 51. Sun Pharma Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 52. Mallinckrodt Revenue Growth Rate in Myotonic Dystrophy Medication Business (2018-2023)

    Figure 53. Bottom-up and Top-down Approaches for This Report

    Figure 54. Data Triangulation

    Figure 55. Key Executives Interviewed